Effect of risedronate on hip structural geometry: A 1-year, double-blind trial in chemotherapy-induced postmenopausal women

Abstract

Introduction-Chemotherapy induced menopause is associated with bone loss. The effect on structural geometry is unknown. Our objective was to determine if oral bisphosphonate therapy could maintain or improve femoral geometry in breast cancer patients with chemotherapy-induced menopause.

Effect of monthly ibandronate on hip structural geometry in men with low bone density

“…Improvements in bone geometric properties have also been reported in women receiving therapy with alendronate [27][28][29] or risedronate [29,30] vs. placebo. Additionally, benefits to hip structural geometry have been observed with non-bisphosphonate osteoporosis treatment options, including raloxifene [31], teriparatide [32][33][34], and denosumab [35].…”

DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass

“…Combination therapy resulted in significantly greater improvements in CSA and estimated CT at the narrow neck and in all parameters at the intertrochanter when compared with hormone monotherapy, but only in CSA and SM at the narrow neck when compared with alendronate monotherapy. In a 1-year study of 81 women with chemotherapy-induced ovarian failure, no significant differences were seen at the narrow neck in any HSAderived geometric parameter in women receiving 35 mg of risedronate weekly compared with placebo [33]. Significant differences compared with placebo were seen at the intertrochanteric and shaft ROIs in the CSA and BR, but not in the SM.…”

The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial

“…Uusi-Rasi et al reported the greatest improvement at the narrow neck with teriparatide treatment [19]. We previously reported the greatest impact of risedronate at the intertrochanteric site, which is composed of more trabecular than cortical bone [20]. The impact of treatment on the ratio of trabecular versus cortical bone may be responsible for some of these differences in site-specific findings.…”

“…The HSA methodology has several limitations [11, 20, 22]. Hip structural analysis is obtained indirectly by mathematical manipulation of two-dimensional data generated by DXA scanners.…”